Significant Milestone in the ANGELICA Trial
CytoMed Therapeutics Limited (NASDAQ: GDTC) is making remarkable strides in clinical research with its ANGELICA Trial. The company has announced the successful completion of Dose Level 1 for its Phase I dose-escalation clinical trial, which focuses on patients with advanced solid tumors and hematological malignancies. This crucial step involves the treatment of four late-stage cancer patients, and the transition to Dose Level 2 is anticipated soon.
Understanding the ANGELICA Trial
The ANGELICA Trial is designed to assess the safety and tolerability of a cutting-edge therapy involving allogeneic NKG2DL-targeting chimeric antigen receptor-grafted (CAR) gamma delta T cells, also known as CTM-N2D. This innovative approach is being evaluated for its effectiveness against various cancer indications, including advanced solid tumors and specific blood cancers.
Mechanism of CTM-N2D Therapy
CTM-N2D leverages a unique subtype of T cells, specifically gamma delta T cells, sourced from healthy donors. These cells are then expanded and genetically modified to express CARs that target NKG2DL, a molecule often found in many forms of cancer. One of the most appealing aspects of this therapy is that it eliminates the necessity for matching donor and patient cells for compatibility, which is often a roadblock in traditional cancer treatments.
Comparative Advantages of CTM-N2D
In contrast to conventional CAR-?? T cell therapies, which involve extracting blood cells from the patient, modifying them, and reinfusing them, CTM-N2D offers a more streamlined and potentially more effective solution. It specifically targets and destroys cancer cells while sparing healthy cells, contrasting with chemotherapy’s broader approach that can affect all actively dividing cells.
The Vision of CytoMed Therapeutics
Founded in 2018, CytoMed Therapeutics was spun off from Singapore’s Agency for Science, Technology and Research (A*STAR). The company’s mission is to harness its proprietary technologies to push the boundaries of biopharmaceutical therapies, particularly focusing on cell-based allogeneic immunotherapies to combat various types of cancer. CytoMed seeks to revolutionize cancer treatment inspired by the successes of existing CAR-T therapies, addressing their limitations in treating solid tumors.
Future Prospects
As CytoMed prepares to initiate Dose Level 2, the company is focusing on the continued development of its unique therapies. The commitment to innovation in treating cancers presents a hopeful outlook for the future of oncology.
Engagement with the Community
CytoMed encourages interested parties to connect with them for more information on their clinical trials and technological advancements. For media inquiries, reach out to Evelyn Tan, Chief Corporate Officer at enquiry@cytomed.sg.
Frequently Asked Questions
What is the ANGELICA Trial?
The ANGELICA Trial is a Phase I clinical trial investigating the safety and efficacy of CTM-N2D, a novel cell therapy targeting various cancers.
How does CTM-N2D work?
CTM-N2D employs gamma delta T cells from healthy donors, modified to target cancer cells without needing patient-donor compatibility.
What makes this therapy different from traditional CAR-T therapies?
This therapy uses donor-derived T cells, allowing for broader application and eliminating compatibility issues seen in patient-derived therapies.
When will Dose Level 2 start?
CytoMed Therapeutics plans to commence Dose Level 2 of the ANGELICA Trial in the third quarter of 2025.
Who can I contact for more information about CytoMed?
For inquiries, please contact Evelyn Tan at enquiry@cytomed.sg.
